Mild parkinsonism in persons exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) produces moderate to severe parkinsonism in humans, but has not been reported to cause a syndrome similar to early Parkinson's disease. We now report 22 cases of mild parkinsonism resulting from exposure to MPTP.
Tetrud
J W
JW
California Parkinson's Foundation, San Jose 95128.
Langston
J W
JW
Garbe
P L
PL
Ruttenber
A J
AJ
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000009:adverse effects*; D000328:Adult; D004185:Disability Evaluation; D006801:Humans; D007275:Injections, Intravenous; D008875:Middle Aged; D009294:Narcotics; D009420:Nervous System / Q000503:physiopathology; D009460:Neurologic Examination; D010302:Parkinson Disease, Secondary / Q000139:chemically induced* / Q000503:physiopathology / Q000523:psychology; D019966:Substance-Related Disorders / Q000503:physiopathology / Q000523:psychology
D009294:Narcotics; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine